Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional bi-specific monoclonal antibody treatment for malignant ascites, a rare complication of advanced-stage cancers. The agreement grants exclusive rights to Pharmanovia to market the antibody, designed for intraperitoneal administration in individuals with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas ineligible for additional systemic anticancer therapies. The gold standard of business intelligence.
The company’s initiative to reintroduce catumaxomab to the market signifies its commitment to expanding its oncology portfolio. Alira Health served as the transaction advisor to Lindis Biotech exclusively, steering the strategic direction and final negotiations of the deal. Lindis Biotech CEO Dr Horst Lindhofer stated: “We are excited to partner with Pharmanovia to support the commercialisation of catumaxomab in Europe.
Both companies share a firm belief in the profound impact this therapy can have on the lives of patients facing this devastating condition and uphold a steadfast commitment to making catumaxomab available to as many people as possible. “Pharmanovia’s supportive care focus, broad European platform and strong expertise in the oncology space make them the ideal partner for us. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will.
